Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32686762 | 0.86 | PDE4B (0.38) | NPC1DGAT1MAPTBRD4CREBBP | |
| SCHEMBL32686826 | 0.85 | NPC1 (0.38) | NPC1DGAT1MAPTALDH1A1 | |
| SCHEMBL32686737 | 0.80 | NPC1 (0.40) | NPC1ALDH1A1 | |
| SCHEMBL8919147 | 0.79 | ALDH1A1 (0.37) | NPC1KDM4EALDH1A1 | |
| SCHEMBL18369614 | 0.75 | MAPT (0.33) | NPC1DGAT1MAPT | |
| SCHEMBL8624806 | 0.74 | HSD17B10 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL25337913 | 0.72 | SIGMAR1 (0.45) | NPC1MAPTALDH1A1 | |
| SCHEMBL18189848 | 0.72 | NPC1 (0.52) | NPC1DGAT1ALDH1A1 | |
| SCHEMBL32686835 | 0.71 | CD74 (0.37) | NPC1MAPTALDH1A1 | |
| SCHEMBL31667359 | 0.71 | NPC1 (0.35) | NPC1DGAT1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NPC1 200/4885DGAT1 1013/4885MAPT 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.